EA201591644A1 - Лекарственная форма, содержащая кризотиниб - Google Patents
Лекарственная форма, содержащая кризотинибInfo
- Publication number
- EA201591644A1 EA201591644A1 EA201591644A EA201591644A EA201591644A1 EA 201591644 A1 EA201591644 A1 EA 201591644A1 EA 201591644 A EA201591644 A EA 201591644A EA 201591644 A EA201591644 A EA 201591644A EA 201591644 A1 EA201591644 A1 EA 201591644A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cryzotinib
- dosage form
- form containing
- tablet
- relates
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780015P | 2013-03-13 | 2013-03-13 | |
| EP13001257 | 2013-03-13 | ||
| PCT/EP2014/054933 WO2014140159A1 (en) | 2013-03-13 | 2014-03-13 | Dosage form comprising crizotinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201591644A1 true EA201591644A1 (ru) | 2016-05-31 |
Family
ID=47900469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591644A EA201591644A1 (ru) | 2013-03-13 | 2014-03-13 | Лекарственная форма, содержащая кризотиниб |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160022661A1 (enExample) |
| EP (1) | EP2968167A1 (enExample) |
| JP (1) | JP2016510787A (enExample) |
| EA (1) | EA201591644A1 (enExample) |
| WO (1) | WO2014140159A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721243B (zh) * | 2017-04-25 | 2022-07-08 | 正大天晴药业集团股份有限公司 | 克唑替尼药物组合物及其制备方法 |
| AU2020417043A1 (en) * | 2019-12-31 | 2022-06-09 | Pfizer Inc. | Stable immediate release tablet and capsule formulations of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US7825137B2 (en) * | 2005-12-05 | 2010-11-02 | Pfizer Inc. | Method of treating abnormal cell growth |
| DE102009015702A1 (de) * | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung |
-
2014
- 2014-03-13 WO PCT/EP2014/054933 patent/WO2014140159A1/en not_active Ceased
- 2014-03-13 EP EP14709950.1A patent/EP2968167A1/en not_active Withdrawn
- 2014-03-13 EA EA201591644A patent/EA201591644A1/ru unknown
- 2014-03-13 JP JP2015562144A patent/JP2016510787A/ja active Pending
- 2014-03-13 US US14/774,072 patent/US20160022661A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016510787A (ja) | 2016-04-11 |
| US20160022661A1 (en) | 2016-01-28 |
| WO2014140159A1 (en) | 2014-09-18 |
| EP2968167A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
| MX2016008098A (es) | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. | |
| EA202092987A3 (ru) | Липид, содержащий докозапентаеновую кислоту | |
| PH12015502293A1 (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
| EA201690246A1 (ru) | Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл | |
| EA201991715A1 (ru) | Композиции, содержащие антитело к pdl1 | |
| EA201400754A2 (ru) | Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| PH12017501035A1 (en) | Method for the production of a pharmaceutical delivery system | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| UA117466C2 (uk) | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 | |
| BR112015030268A2 (pt) | composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição | |
| EA201591618A1 (ru) | Замещенные имидазопиридазины | |
| MX345926B (es) | Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas. | |
| MX2016008369A (es) | Composicion farmaceutica que incluye palonosetron. | |
| PH12014502856A1 (en) | Solid pharmaceutical preparation containing levothyroxine | |
| BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
| IN2013MU03641A (enExample) | ||
| EA201691299A1 (ru) | Применение лахинимода для замедления прогрессирования болезни хантингтона | |
| MX2015016603A (es) | Composiciones de corticosteroides. | |
| EA201591644A1 (ru) | Лекарственная форма, содержащая кризотиниб |